



17W

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Chwalisz

Group Art No.: 1614

Serial No.: 10/714,219

Examiner: Not yet assigned


Filed: November 14, 2003

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450, on:

Title: USE OF SELECTIVE
PROGESTERONE RECEPTOR
MODULATORS FOR THE TREATMENT
OF ANDROGEN DEFICIENCY

Date of Deposit: July 21, 2004

Case No.: 6999.US.O2

 7/21/04
Jenny Rizzotto Date

TRANSMITTAL LETTER

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith for the patent application identified above entitled USE OF SELECTIVE PROGESTERONE RECEPTOR MODULATORS FOR THE TREATMENT OF ANDROGEN DEFICIENCY, are the following:


1. Information Disclosure Statement;
2. Copy of Search Report from PCT/US03/37182
3. Form PTO 1449, in duplicate;
4. References as cited on PTO 1449 (8 References); and
5. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR § 1.16, as well as any patent application processing fees under 37 CFR § 1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

23492

ABBOTT LABORATORIES
Telephone: (847) 938-3508
Facsimile: (847) 938-2623

Respectfully submitted,
Chwalisz.


Paul D. Yasper
Registration No. 37,477
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Chwalisz

Serial No.: 10/714,219

Filed: November 14, 2003

Title: USE OF SELECTIVE
PROGESTERONE RECEPTOR
MODULATORS FOR THE TREATMENT
OF ANDROGEN DEFICIENCY


Case No.: 6999.US.O2

Group Art No.: 1614

Examiner: Not yet assigned

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450, on:

Date of Deposit: July 21, 2004

 7/21/04
Jenny Rizzotto Date

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicant respectfully petitions and requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.


The undersigned certifies that each item contained in this Information Disclosure Statement were first cited in a communication from a Foreign Patent Office by the European Patent Office in a counterpart international PCT application not more than three months prior to the filing of the information disclosure statement. Therefore, no fee is required.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

23492

ABBOTT LABORATORIES
Telephone: (847) 938-3508
Facsimile: (847) 938-2623

Respectfully submitted,
Chwalisz


Paul D. Yasger
Registration No. 37,477
Attorney for Applicants



DATE: July 21, 2004

SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6999.US.O2

SERIAL NO.

10/714,219

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)

Chwalisz

FILING DATE

November 14, 2003

GROUP

1614

(37 CFR 1.98 (b))

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION
	B1	01/15679	08.03.2001	WO			YES NO
	B2	01/34126	17.05.2001	WO			YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Rosen, "Sexual Pharmacology in the 21 st Century", Journal of Gender-Specific Medicine, 3 (5), 45-52 (2000)
C2	Spitz, "Progesterone antagonists and progesterone receptor modulators: an overview", Steroids, 68, 981-993 (2003)
C3	Demanno et al, "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy", Steroids, 68, 1019-1032 (2003)
C4	Elger et al, "Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity", Steroids, 65, 713-723 (2000)
C5	Schmid et al, "Sildenafil in the Treatment of Sexual Dysfunction of Spinal Cord-Injured Male Patients", European Urology, 38, 184-193 (2000)
C6	Chwalisz et al, "Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium", Steroids, 65, 741-751 (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)